Skip to main content

Advertisement

SpringerLink
Log in

Emerging Pharmacologic Treatments for Adolescent Substance Use: Challenges and New Directions

  • Adolescent Substance Abuse (T Chung, Section Editor)
  • Published:
Current Addiction Reports Aims and scope Submit manuscript

Abstract

Adolescence is a key period in the development of substance use and misuse. Substance use typically begins during adolescence, and prevalence rates for many substance use disorders peak before age 21 years. Yet, despite clinical demand, treatments for youth rely almost entirely on psychosocial interventions that yield only modest benefit. One potential way to improve treatment effects is to augment the best available psychosocial interventions with pharmacotherapy. Although pharmacotherapy research has advanced care for adults with substance use disorders, no medication is indicated for adolescents and controlled trials with teenagers are scant. Optimizing treatments for youth will require closing this important gap in medication development research. In this paper, we review the paucity of pharmacotherapy research for adolescent substance misuse, and we discuss how we can leverage human laboratory paradigms and technology to advance our understanding regarding if and how medications may improve treatment options for youths.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Hingson R, White A. New research findings since the 2007 Surgeon General’s Call to Action to Prevent and Reduce Underage Drinking: a review. J Stud Alcohol Drugs. 2014;75(1):158–69.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Swendsen J, Burstein M, Case B, Conway KP, Dierker L, He J, et al. Use and abuse of alcohol and illicit drugs in US adolescents: results of the National Comorbidity Survey-Adolescent Supplement. Arch Gen Psychiatry. 2012;69(4):390–8.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Services USDoHaH. The Surgeon General’s Call to Action to Prevent and Reduce Underage Drinking. 2007.

  4. Johnston LD, O’Malley PM, Miech RA, Bachman JG, Schulenberg J. Monitoring the Future Results on Drug Use: 1975–2014: Overview of Key Findings. 2015.

  5. The National Center on Addiction and Substance Abuse (CASA) at Columbia University. Adolescent substance use: America’s #1 Public Health Problem. Atlanta, GA.2011.

  6. Center for Behavioral Health Statistics and Quality. 2014 National Survey on Drug Use and Health: Detailed Tables. In: Substance Abuse and Mental Health Services Administration. Rockville, MD.2015.

  7. Lubman DI, Yucel M, Hall WD. Substance use and the adolescent brain: a toxic combination? J Psychopharmacol. 2007;21(8):792–4.

    Article  PubMed  Google Scholar 

  8. Volkow N, Li TK. The neuroscience of addiction. Nat Neurosci. 2005;8(11):1429–30.

    Article  CAS  PubMed  Google Scholar 

  9. Schneider M. Puberty as a highly vulnerable developmental period for the consequences of cannabis exposure. Addict Biol. 2008;13(2):253–63.

    Article  PubMed  Google Scholar 

  10. Behrendt S, Wittchen HU, Hofler M, Lieb R, Beesdo K. Transitions from first substance use to substance use disorders in adolescence: is early onset associated with a rapid escalation? Drug Alcohol Depend. 2009;99(1–3):68–78.

    Article  CAS  PubMed  Google Scholar 

  11. Chen CY, Storr CL, Anthony JC. Early-onset drug use and risk for drug dependence problems. Addict Behav. 2009;34(3):319–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Dawson DA, Goldstein RB, Chou SP, Ruan WJ, Grant BF. Age at first drink and the first incidence of adult-onset DSM-IV alcohol use disorders. Alcohol Clin Exp Res. 2008;32(12):2149–60.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Hingson RW, Zha W. Age of drinking onset, alcohol use disorders, frequent heavy drinking, and unintentionally injuring oneself and others after drinking. Pediatrics. 2009;123(6):1477–84.

    Article  PubMed  Google Scholar 

  14. Hingson RW, Heeren T, Winter MR. Age at drinking onset and alcohol dependence: age at onset, duration, and severity. Arch Pediatr Adolesc Med. 2006;160(7):739–46.

    Article  PubMed  Google Scholar 

  15. Wagner FA, Anthony JC. From first drug use to drug dependence; developmental periods of risk for dependence upon marijuana, cocaine, and alcohol. Neuropsychopharmacol: Off Publ Am Coll Neuropsychopharmacol. 2002;26(4):479–88.

    Article  Google Scholar 

  16. Lopez-Quintero C, Perez de los Cobos J, Hasin DS, Okuda M, Wang S, Grant BF, et al. Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Drug Alcohol Depend. 2011;115(1–2):120–30.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Winters KC, Tanner-Smith EE, Bresani E, Meyers K. Current advances in the treatment of adolescent drug use. Adolesc Health Med Ther. 2014;5:199–210.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Lord S, Marsch L. Emerging trends and innovations in the identification and management of drug use among adolescents and young adults. Adolesc Med State Art Rev. 2011;22(3):649–69. xiv.

    PubMed  PubMed Central  Google Scholar 

  19. Tanner-Smith EE, Lipsey MW. Brief alcohol interventions for adolescents and young adults: a systematic review and meta-analysis. J Subst Abus Treat. 2015;51:1–18.

    Article  Google Scholar 

  20. Carney T, Myers B. Effectiveness of early interventions for substance-using adolescents: findings from a systematic review and meta-analysis. Subst Abuse Treat Prev Policy. 2012;7:25.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Jensen CD, Cushing CC, Aylward BS, Craig JT, Sorell DM, Steele RG. Effectiveness of motivational interviewing interventions for adolescent substance use behavior change: a meta-analytic review. J Consult Clin Psychol. 2011;79(4):433–40.

    Article  PubMed  Google Scholar 

  22. Belendiuk KA, Riggs P. Treatment of adolescent substance use disorders. Curr Treat Options Psychiatry. 2014;1(2):175–88.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Black JJ, Chung T. Mechanisms of change in adolescent substance use treatment: how does treatment work? Subst Abus : Off Publ Assoc Med Educ Res Subst Abuse. 2014;35(4):344–51.

    Article  Google Scholar 

  24. Mitchell SG, Gryczynski J, O’Grady KE, Schwartz RP. SBIRT for adolescent drug and alcohol use: current status and future directions. J Subst Abus Treat. 2013;44(5):463–72.

    Article  Google Scholar 

  25. Clark DB. Pharmacotherapy for adolescent alcohol use disorder. CNS Drugs. 2012;26(7):559–69.

    Article  CAS  PubMed  Google Scholar 

  26. Courtney DB, Milin R. Pharmacotherapy for adolescents with substance use disorders. Curr Treat Options Psychiatry. 2015;2(3):312–25.

    Article  Google Scholar 

  27. Waxmonsky JG, Wilens TE. Pharmacotherapy of adolescent substance use disorders: a review of the literature. J Child Adolesc Psychopharmacol. 2005;15(5):810–25.

    Article  PubMed  Google Scholar 

  28. Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, Pincus HA, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA. 2007;297(15):1683–96.

    Article  CAS  PubMed  Google Scholar 

  29. Mayes TL, Tao R, Rintelmann JW, Carmody T, Hughes CW, Kennard BD, et al. Do children and adolescents have differential response rates in placebo-controlled trials of fluoxetine? CNS Spectrums. 2007;12(2):147–54.

    PubMed  Google Scholar 

  30. Safer DJ. A comparison of risperidone-induced weight gain across the age span. J Clin Psychopharmacol. 2004;24(4):429–36.

    Article  CAS  PubMed  Google Scholar 

  31. Simkin DR, Grenoble S. Pharmacotherapies for adolescent substance use disorders. Child Adolesc Psychiatr Clin N Am. 2010;19(3):591–608.

    Article  PubMed  Google Scholar 

  32. Brown SA, McGue M, Maggs J, Schulenberg J, Hingson R, Swartzwelder S, et al. A developmental perspective on alcohol and youths 16 to 20 years of age. Pediatrics. 2008;121 Suppl 4:S290–310.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Spear LP. Adolescents and alcohol: acute sensitivities, enhanced intake, and later consequences. Neurotoxicol Teratol. 2014;41:51–9.

    Article  CAS  PubMed  Google Scholar 

  34. Upadhyaya H, Deas D. Pharmacological interventions for adolescent substance use disorders. In: Kaminer Y, Bukstein OG, editors. Adolescent substance abuse: psychiatric comorbidity and high-risk behaviors. New York, NY: Routledge; 2008. p. 145–61.

    Google Scholar 

  35. Bailey JA, Samek DR, Keyes MA, Hill KG, Hicks BM, McGue M, et al. General and substance-specific predictors of young adult nicotine dependence, alcohol use disorder, and problem behavior: replication in two samples. Drug Alcohol Depend. 2014;138:161–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Kim Y, Myung SK, Jeon YJ, Lee EH, Park CH, Seo HG, et al. Effectiveness of pharmacologic therapy for smoking cessation in adolescent smokers: meta-analysis of randomized controlled trials. Am J Health Syst Pharm. 2011;68(3):219–26.

    Article  CAS  PubMed  Google Scholar 

  37. Giedd JN. Structural magnetic resonance imaging of the adolescent brain. Ann N Y Acad Sci. 2004;1021:77–85.

    Article  PubMed  Google Scholar 

  38. O’Malley SS, Corbin WR, Leeman RF, DeMartini KS, Fucito LM, Ikomi J, et al. Reduction of alcohol drinking in young adults by naltrexone: a double-blind, placebo-controlled, randomized clinical trial of efficacy and safety. J Clin Psychiatry. 2015;76(2):e207–13.

    Article  PubMed  PubMed Central  Google Scholar 

  39. DeMartini KS, Gueorguiva R, Leeman RF, Corbin WR, Fucito LM, Kranzler HR, et al. Naltrexone for non-treatment seeking young adult drinkers: one-year outcomes. Alcohlism : Clin Exp Res. 2014;38(Supplement 1):212A. This article describes the follow-up to a recent double-blind, placebo-controlled, randomized trial of naltrexone for treating alcohol misuse among young adults. This study reflects one of the few adequately power RCTs of a medication for treating alcohol misuse in young adulthood.

  40. Bailey SR, Crew EE, Riske EC, Ammerman S, Robinson TN, Killen JD. Efficacy and tolerability of pharmacotherapies to aid smoking cessation in adolescents. Paediatr Drugs. 2012;14(2):91–108.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Gray KM, Carpenter MJ, Baker NL, Hartwell KJ, Lewis AL, Hiott DW, et al. Bupropion SR and contingency management for adolescent smoking cessation. J Subst Abus Treat. 2011;40(1):77–86.

    Article  Google Scholar 

  42. Gray KM, Carpenter MJ, Lewis AL, Klintworth EM, Upadhyaya HP. Varenicline versus bupropion XL for smoking cessation in older adolescents: a randomized, double-blind pilot trial. Nicotine Tob Res : Off J Soc Res Nicotine Tob. 2012;14(2):234–9.

    Article  CAS  Google Scholar 

  43. Scherphof CS, van den Eijnden RJ, Engels RC, Vollebergh WA. Short-term efficacy of nicotine replacement therapy for smoking cessation in adolescents: a randomized controlled trial. J Subst Abus Treat. 2014;46(2):120–7. This article describes a recent randomized, double-blind, placebo-controlled trial of the efficacy and safety of nicotine replacement therapy for adolescent smokers. Findings from this study suggest that nicotine replacement therapy, namely, nicotine patches, may prove beneficial for helping adolescents—particularly those who are highly compliant with the treatment regimen—achieve smoking cessation.

  44. Mason BJ, Crean R, Goodell V, Light JM, Quello S, Shadan F, et al. A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacol:Off Publ Am Coll Neuropsychopharmacol. 2012;37(7):1689–98.

    Article  CAS  Google Scholar 

  45. Gray KM, Carpenter MJ, Baker NL, DeSantis SM, Kryway E, Hartwell KJ, et al. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatry. 2012;169(8):805–12.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Miranda R, Jr., Treloar H, Blanchard A, Justus A, Monti PM, Chun T, et al. Topiramate and motivational enhancement therapy for cannabis use among youth: a randomized placebo-controlled pilot study. Addicton Biology. In press. This article describes a recent double-blind, placebo-controlled, randomized trial of topiramate for treating cannabis misuse among adolescents and young adults. This is the first and only study of topiramate’s effects of cannabis among adolescents or adults.

  47. Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003;361(9370):1677–85.

    Article  CAS  PubMed  Google Scholar 

  48. Johnson BA, Ait-Daoud N, Wang XQ, Penberthy JK, Javors MA, Seneviratne C, et al. Topiramate for the treatment of cocaine addiction: a randomized clinical trial. JAMA Psychiatry. 2013;70(12):1338–46.

    Article  CAS  PubMed  Google Scholar 

  49. Kranzler HR, Covault J, Feinn R, Armeli S, Tennen H, Arias AJ, et al. Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism. Am J Psychiatry. 2014;171(4):445–52.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Miranda Jr R, MacKillop J, Monti PM, Rohsenow DJ, Tidey J, Gwaltney C, et al. Effects of topiramate on urge to drink and the subjective effects of alcohol: a preliminary laboratory study. Alcohol Clin Exp Res. 2008;32(3):489–97.

    Article  CAS  PubMed  Google Scholar 

  51. Miranda Jr R, MacKillop J, Treloar H, Blanchard A, Tidey JW, Swift RM, et al. Biobehavioral mechanisms of topiramate’s effects on alcohol use: an investigation pairing laboratory and ecological momentary assessments. Addict Biol. 2014.

  52. Oncken C, Arias AJ, Feinn R, Litt M, Covault J, Sofuoglu M, et al. Topiramate for smoking cessation: a randomized, placebo-controlled pilot study. Nicotine Tob Res : Off J Soc Res Nicotine Tob. 2014;16(3):288–96.

    Article  CAS  Google Scholar 

  53. Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia. 2000;41 Suppl 1:S3–9.

    Article  CAS  PubMed  Google Scholar 

  54. Simeone TA, Wilcox KS, White HS. Subunit selectivity of topiramate modulation of heteromeric GABA(A) receptors. Neuropharmacology. 2006;50(7):845–57.

    Article  CAS  PubMed  Google Scholar 

  55. Marsch LA, Bickel WK, Badger GJ, Stothart ME, Quesnel KJ, Stanger C, et al. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial. Arch Gen Psychiatry. 2005;62(10):1157–64.

    Article  CAS  PubMed  Google Scholar 

  56. Woody GE, Poole SA, Subramaniam G, Dugosh K, Bogenschutz M, Abbott P, et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA. 2008;300(17):2003–11.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Heinzerling KG, Gadzhyan J, van Oudheusden H, Rodriguez F, McCracken J, Shoptaw S. Pilot randomized trial of bupropion for adolescent methamphetamine abuse/dependence. J Adolesc Health : Off Publ Soc Adolesc Med. 2013;52(4):502–5.

    Article  Google Scholar 

  58. Zhou X, Qin B, Del Giovane C, Pan J, Gentile S, Liu Y, et al. Efficacy and tolerability of antidepressants in the treatment of adolescents and young adults with depression and substance use disorders: a systematic review and meta-analysis. Addiction. 2015;110(1):38–48. This systematic review article provides a meta-analysis of the efficacy and tolerability of antidepressants for treating co-morbid substance use disorders and depression among youth. Given the high levels of co-morbidity between depression and substance use disorders among adolescents, this article provides an important overview and discussion regarding the importance of integrated treatments for these co-occurring conditions.

  59. Riggs PD, Mikulich-Gilbertson SK, Davies RD, Lohman M, Klein C, Stover SK. A randomized controlled trial of fluoxetine and cognitive behavioral therapy in adolescents with major depression, behavior problems, and substance use disorders. Arch Pediatr Adolesc Med. 2007;161(11):1026–34.

    Article  PubMed  Google Scholar 

  60. Cornelius JR, Bukstein OG, Douaihy AB, Clark DB, Chung TA, Daley DC, et al. Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults. Drug Alcohol Depend. 2010;112(1–2):39–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Cornelius JR, Bukstein OG, Wood DS, Kirisci L, Douaihy A, Clark DB. Double-blind placebo-controlled trial of fluoxetine in adolescents with comorbid major depression and an alcohol use disorder. Addict Behav. 2009;34(10):905–9.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Riggs PD, Hall SK, Mikulich-Gilbertson SK, Lohman M, Kayser A. A randomized controlled trial of pemoline for attention-deficit/hyperactivity disorder in substance-abusing adolescents. J Am Acad Child Adolesc Psychiatry. 2004;43(4):420–9.

    Article  PubMed  Google Scholar 

  63. Thurstone C, Riggs PD, Salomonsen-Sautel S, Mikulich-Gilbertson SK. Randomized, controlled trial of atomoxetine for attention-deficit/hyperactivity disorder in adolescents with substance use disorder. J Am Acad Child Adolesc Psychiatry. 2010;49(6):573–82.

    PubMed  PubMed Central  Google Scholar 

  64. Wilens TE, Adler LA, Weiss MD, Michelson D, Ramsey JL, Moore RJ, et al. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Drug Alcohol Depend. 2008;96(1–2):145–54.

    Article  CAS  PubMed  Google Scholar 

  65. Riggs PD, Winhusen T, Davies RD, Leimberger JD, Mikulich-Gilbertson S, Klein C, et al. Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders. J Am Acad Child Adolesc Psychiatry. 2011;50(9):903–14.

    Article  PubMed  PubMed Central  Google Scholar 

  66. McKee SA, Weinberger AH, Shi J, Tetrault J, Coppola S. Developing and validating a human laboratory model to screen medications for smoking cessation. Nicotine Tob Res : Off J Soc Res Nicotine Tob. 2012;14(11):1362–71.

    Article  CAS  Google Scholar 

  67. Litten RZ, Ryan ML, Falk DE, Reilly M, Fertig JB, Koob GF. Heterogeneity of alcohol use disorder: understanding mechanisms to advance personalized treatment. Alcohol Clin Exp Res. 2015;39(4):579–84.

    Article  PubMed  Google Scholar 

  68. Cuthbert BN. The RDoC framework: facilitating transition from ICD/DSM to dimensional approaches that integrate neuroscience and psychopathology. World Psychiatry. 2014;13(1):28–35.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Cuthbert BN, Insel TR. Toward the future of psychiatric diagnosis: the seven pillars of RDoC. BMC Med. 2013;11:126.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Leggio L, Zywiak WH, Edwards SM, Tidey JW, Swift RM, Kenna GA. A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers. Psychopharmacology. 2015;232(1):233–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Davidson D, Palfai T, Bird C, Swift R. Effects of naltrexone on alcohol self-administration in heavy drinkers. Alcohol Clin Exp Res. 1999;23(2):195–203.

    Article  CAS  PubMed  Google Scholar 

  72. Davidson D, Swift R, Fitz E. Naltrexone increases the latency to drink alcohol in social drinkers. Alcohol Clin Exp Res. 1996;20(4):732–9.

    Article  CAS  PubMed  Google Scholar 

  73. Drummond DC. Theories of drug craving, ancient and modern. Addiction. 2001;96(1):33–46.

    Article  CAS  PubMed  Google Scholar 

  74. Tiffany ST, Wray JM. The clinical significance of drug craving. Ann N Y Acad Sci. 2012;1248:1–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. O’Brien CP. Anticraving medications for relapse prevention: a possible new class of psychoactive medications. Am J Psychiatry. 2005;162(8):1423–31.

    Article  PubMed  Google Scholar 

  76. American Psychiatric Association., American Psychiatric Association. DSM-5 Task Force. Diagnostic and statistical manual of mental disorders : DSM-5. 5th ed. Washington, D.C.: American Psychiatric Association; 2013. xliv, 947 p. p.

  77. Ramirez J, Miranda Jr R. Alcohol craving in adolescents: bridging the laboratory and natural environment. Psychopharmacology. 2014;231(8):1841–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Spear LP. Adolescent neurobehavioral characteristics, alcohol sensitivities, and intake: setting the stage for alcohol use disorders? Child Dev Perspect. 2011;5(4):231–8.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Spear LP, Varlinskaya EI. Sensitivity to ethanol and other hedonic stimuli in an animal model of adolescence: implications for prevention science? Dev Psychobiol. 2010;52(3):236–43.

    CAS  PubMed  PubMed Central  Google Scholar 

  80. Behar D, Berg CJ, Rapoport JL, Nelson W, Linnoila M, Cohen M, et al. Behavioral and physiological effects of ethanol in high-risk and control children: a pilot study. Alcohol Clin Exp Res. 1983;7(4):404–10.

    Article  CAS  PubMed  Google Scholar 

  81. Collins RL, Morsheimer ET, Shiffman S, Paty JA, Gnys M, Papandonatos GD. Ecological momentary assessment in a behavioral drinking moderation training program. Exp Clin Psychopharmacol. 1998;6(3):306–15.

    Article  CAS  PubMed  Google Scholar 

  82. Gwaltney CJ, Shiffman S, Paty JA, Liu KS, Kassel JD, Gnys M, et al. Using self-efficacy judgments to predict characteristics of lapses to smoking. J Consult Clin Psychol. 2002;70(5):1140–9.

    Article  PubMed  Google Scholar 

  83. Muraven M, Collins RL, Morsheimer ET, Shiffman S, Paty JA. One too many: predicting future alcohol consumption following heavy drinking. Exp Clin Psychopharmacol. 2005;13(2):127–36.

    Article  PubMed  Google Scholar 

  84. Muraven M, Collins RL, Morsheimer ET, Shiffman S, Paty JA. The morning after: limit violations and the self-regulation of alcohol consumption. Psychol Addict behav : J Soc Psychol Addict Behav. 2005;19(3):253–62.

    Article  Google Scholar 

  85. Muraven M, Collins RL, Shiffman S, Paty JA. Daily fluctuations in self-control demands and alcohol intake. Psychol Addict Behav : J Soc Psychol Addict Behav. 2005;19(2):140–7.

    Article  Google Scholar 

  86. Shiffman S, Patten C, Gwaltney C, Paty J, Gnys M, Kassel J, et al. Natural history of nicotine withdrawal. Addiction. 2006;101(12):1822–32.

    Article  PubMed  Google Scholar 

  87. Miranda Jr R, Monti PM, Ray L, Treloar HR, Reynolds EK, Ramirez J, et al. Characterizing subjective responses to alcohol among adolescent problem drinkers. J Abnorm Psychol. 2014;123(1):117–29.

    Article  PubMed  PubMed Central  Google Scholar 

  88. Piasecki TM, Jahng S, Wood PK, Robertson BM, Epler AJ, Cronk NJ, et al. The subjective effects of alcohol-tobacco co-use: an ecological momentary assessment investigation. J Abnorm Psychol. 2011;120(3):557–71.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Piasecki TM, Trela CJ, Hedeker D, Mermelstein RJ. Smoking antecedents: separating between- and within-person effects of tobacco dependence in a multiwave ecological momentary assessment investigation of adolescent smoking. Nicotine Tob Res : Off J Soc Res Nicotine Tob. 2014;16 Suppl 2:S119–26.

    Article  CAS  Google Scholar 

  90. Treloar HR, Piasecki TM, McCarthy DE, Baker TB. Relations among caffeine consumption, smoking, smoking urge, and subjective smoking reinforcement in daily life. J Caffeine Res. 2014;4(3):93–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Treloar H, Piasecki TM, McCarthy DM, Sher KJ, Heath AC. Ecological evidence that affect and perceptions of drink effects depend on alcohol expectancies. Addiction. 2015;110(9):1432–42.

    Article  PubMed  Google Scholar 

  92. Hufford MR, Shields AL, Shiffman S, Paty J, Balabanis M. Reactivity to ecological momentary assessment: an example using undergraduate problem drinkers. Psychol Addict Behav : J Soc Psychol Addict Behav. 2002;16(3):205–11.

    Article  Google Scholar 

  93. Litt MD, Cooney NL, Morse P. Ecological momentary assessment (EMA) with treated alcoholics: methodological problems and potential solutions. Health Psychol : Off J Div Health Psychol Am Psychol Assoc. 1998;17(1):48–52.

    Article  CAS  Google Scholar 

  94. Miranda R, Ray L, Blanchard A, Reynolds EK, Monti PM, Chun T, et al. Effects of naltrexone on adolescent alcohol cue reactivity and sensitivity: an initial randomized trial. Addict Biol. 2014;19(5):941–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction. 2013;108(2):275–93.

    Article  PubMed  PubMed Central  Google Scholar 

  96. Worley MJ, Witkiewitz K, Brown SA, Kivlahan DR, Longabaugh R. Social network moderators of naltrexone and behavioral treatment effects on heavy drinking in the COMBINE study. Alcohol Clin Exp Res. 2015;39(1):93–100.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Hanson K, Allen S, Jensen S, Hatsukami D. Treatment of adolescent smokers with the nicotine patch. Nicotine Tob Res : Off J Soc Res Nicotine Tob. 2003;5(4):515–26.

    Article  Google Scholar 

  98. Killen JD, Robinson TN, Ammerman S, Hayward C, Rogers J, Stone C, et al. Randomized clinical trial of the efficacy of bupropion combined with nicotine patch in the treatment of adolescent smokers. J Consult Clin Psychol. 2004;72(4):729–35.

    Article  PubMed  Google Scholar 

  99. Moolchan ET, Robinson ML, Ernst M, Cadet JL, Pickworth WB, Heishman SJ, et al. Safety and efficacy of the nicotine patch and gum for the treatment of adolescent tobacco addiction. Pediatrics. 2005;115(4):e407–14.

    Article  PubMed  Google Scholar 

  100. Roddy E, Romilly N, Challenger A, Lewis S, Britton J. Use of nicotine replacement therapy in socioeconomically deprived young smokers: a community-based pilot randomised controlled trial. Tob Control. 2006;15(5):373–6.

    Article  PubMed  PubMed Central  Google Scholar 

  101. Muramoto ML, Leischow SJ, Sherrill D, Matthews E, Strayer LJ. Randomized, double-blind, placebo-controlled trial of 2 dosages of sustained-release bupropion for adolescent smoking cessation. Arch Pediatr Adolesc Med. 2007;161(11):1068–74.

    Article  PubMed  Google Scholar 

  102. Rubinstein ML, Benowitz NL, Auerback GM, Moscicki AB. A randomized trial of nicotine nasal spray in adolescent smokers. Pediatrics. 2008;122(3):e595–600.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

The National Institute on Alcohol Abuse and Alcoholism at the National Institutes of Health supported this work (AA07850). The funding source had no role in this research other than financial support. We thank Alexander Blanchard for his help with the literature review for this article.

Author information

Authors and Affiliations

  1. Center for Alcohol and Addiction Studies, Brown University, Box S121-5, Providence, RI, 02912, USA

    Robert Miranda Jr. & Hayley Treloar

Authors
  1. Robert Miranda Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hayley Treloar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert Miranda Jr..

Ethics declarations

Conflict of Interest

Robert Miranda Jr. and Hayley Treloar declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors. Informed consent was obtained from all individual participants included in the study.

Additional information

This article is part of the Topical Collection on Adolescent Substance Abuse

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Miranda, R., Treloar, H. Emerging Pharmacologic Treatments for Adolescent Substance Use: Challenges and New Directions. Curr Addict Rep 3, 145–156 (2016). https://doi.org/10.1007/s40429-016-0098-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40429-016-0098-7

Keywords

Search

Navigation